Poseidon Innovation LLC and the University of California have patented bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, viral infections and acute renal disorders, among others.

University of Maryland has presented proteolysis targeting chimeras (PROTACs) comprised of E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to induced myeloid leukemia cell differentiation protein Mcl-1-binding moiety through a linker reported to be useful for the treatment of cancer.

Avelos Therapeutics Inc. has identified substituted 1,2-diaminoheterocyclic compound derivatives acting as serine/threonine-protein kinase greatwall (MASTL) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity, stroke, thrombosis deep venous, thrombocytopenia and cardiovascular disorders.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged pyrrolopyridines acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer.

Genfleet Therapeutics (Shanghai) Inc. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of stroke, rheumatoid arthritis, psoriasis, heart failure, nonalcoholic steatohepatitis and inflammatory bowel disease.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising of E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton tyrosine kinase (BTK) binding moiety through a linker. They are reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.

Vertex Pharmaceuticals Inc. has divulged N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-Tooth disease, cough, urinary incontinence and multiple sclerosis.

Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Senhui Pharmaceutical Co. Ltd. have identified pyridine compounds acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infections.

Council of Scientific and Industrial Research (India) has synthesized substituted tricyclic heterocyclic compounds acting as β-lactamase IMP-1 (bacterial) and/or New Delhi metallo-β-lactamase-1 (NDM-1) (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.

Genentech Inc. has disclosed 2,8-diazaspiro [4.5] decane compounds acting as serine/threonine-protein kinase LATS1 and/or LATS2 inhibitors reported to be useful for the treatment of acute respiratory distress syndrome (ARDS).